Company Directory - Research & Development
Working at the frontier of biotechnology and medicine, our mission is to develop therapeutics to extend the period of one’s life unburdened by disease. Our initial focus is on delivering localized therapy in ophthalmologic diseases, including diabetic macular edema and age-related macular degeneration, and age-related neurologic conditions.
VSY Biotechnology GmbH is an innovation driven company with its progressive R&D activities in ophthalmology, orthopedics, aesthetics and biotechnologic drugs. VSY Biotechnology focuses on developing, designing and manufacturing superior state-of-the-art products to serve doctors, patients and consumers beyond their expectations.
Valneva is a specialty vaccine company providing prevention against diseases with major unmet medical needs. The Company has a growing commercial business with two successful vaccines for travelers. Our focused pipeline includes the only Lyme disease vaccine candidate in clinical development today and the only single-shot chikungunya vaccine candidate.
We are a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Veeprho is Certified Pharmaceutical Impurity Reference Standards Supplier and Manufacturer in Europe, USA, UK. We are involved in the research, development, and distribution of synthesized impurities, metabolites, intermediates, and custom synthesis.
We aim to improve health and quality of life for the millions of people affected by chronic respiratory diseases. Our first-in-class development candidate, ensifentrine (RPL554), has the potential to provide relief for patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD), COVID-19, cystic fibrosis (CF) and asthma.
Versantis is a clinical-stage biotech company developing transformative orphan drugs in liver and pediatric diseases. Founded by leading scientists from ETH Zurich and industry experts, Versantis' mission is to provide quality therapeutic solutions to revolutionize the critical care of cirrhosis decompensations and neonatal hyperammonemic crises.
Vincerx Pharma (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer.
We are a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. We are taking a multi-program, multi-technology platform approach, assembled through internal development, collaborations, and acquisitions.
Vivoryon Therapeutics has two decades of successful history in bringing pharmaceutical innovation to patients in need. Our programs are based on dedicated research, top-level discovery and determined development.
We are tackling some of the most difficult challenges in genomic research. This demands science at scale; a visionary and creative approach to research that pushes the boundaries of our understanding in ever new and exciting ways.
Wren Therapeutics is a spin-off company from the University of Cambridge (UK) and Lund University (Sweden) focussed on protein misfolding diseases. Wren Therapeutics is advancing an entirely novel approach to address this class of diseases, based on decades of research from its scientific founders focused on the chemical kinetics of the protein misfolding process.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology.
bioeq GmbH is active in the development of biosimilar drugs for global markets in compliance with the stringent quality standards required for approval and distribution in the EU, US and other highly regulated countries. Therefore quality platforms according to current GCP and GMP standards are established.
c-LEcta is a fully integrated industrial biotechnology company located in Leipzig, Germany. The company currently employs about 100 people and has established itself as leading player in the realization of high-value biotech products for regulated markets, either as in-house developments or in close cooperation with the industry.
o2h discovery is a premier Contract Research Organisation providing integrated chemistry and biology services for collaborative research.
riboxx pharmaceuticals develops and manufactures GMP TLR3 ligands for immunotherapy of cancer or virus diseases. The drugs developed at riboxx belong to the class of Toll-like-Receptor 3 agonists (TLR3) and RIG-I-like-Receptor (RLR) agonists. The drug substance of these drugs is RNA (ribonucleic acid).
